Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass Michael McClung, MD – Oregon Osteoporosis Center
9:00 AM – 11:00 AM ET
Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study Diana Camelia Dan, MD – Lausanne University Hospital
9:00 AM – 11:00 AM ET
The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative Rachel E. Elam, MD – Augusta University
9:00 AM – 11:00 AM ET
Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis Zoltan Szekanecz, MD, PhD – University of Debrecen
9:00 AM – 11:00 AM ET
Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients Zoltan Szekanecz, MD, PhD – University of Debrecen
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation David W Dempster, PhD – Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY
9:00 AM – 11:00 AM ET
The Relationship Between Body Fat Percentage and Bone Mineral Density in Rheumatoid Arthritis Patients Anastasia- Vasiliki Madenidou, MD, MSc – Stepping Hill Hospital
9:00 AM – 11:00 AM ET
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention? Eileen Rife, MD – Louisiana State University
9:00 AM – 11:00 AM ET
Pharmacist-Driven Clinic Development for Patients with Incidental Vertebral or Hip Fractures Julie O. Ferm, PharmD – UF Health Jacksonville
9:00 AM – 11:00 AM ET
Does Urate Directly Influence Bone Turnover? Randomized Controlled Trial of Inosine Supplementation Nicola Dalbeth, MD – University of Auckland
9:00 AM – 11:00 AM ET
Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic Shikha Singla, MD – MCW
9:00 AM – 11:00 AM ET
Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy David Montero, MD – Osakidetza
9:00 AM – 11:00 AM ET
Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines Marielys Figueroa Sierra, MD, MS – University of South Florida
9:00 AM – 11:00 AM ET
Incidence of Follow-Up Dual-Energy X-Ray Absorptiometry Scanner Error: A Contributor to Precision Error Kevin Lee, MD, BSc – University of Alberta
9:00 AM – 11:00 AM ET
Improving Osteoporosis Screening in Men at a Resident-run Primary Care Clinic: A Quality Improvement Project Khiem Vu, MD – Grand Strand Medical Center
9:00 AM – 11:00 AM ET
The in Vitro 3D Fracture Gap Model: A Tool for Preclinical Testing Moritz Pfeiffenberger, MSc – Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology
9:00 AM – 11:00 AM ET
Development of an In Vitro Trabecular Human Bone Model to Recapitulate Features of Glucocorticoid-induced Osteoporosis Timo Gaber, PhD, MSc – Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology
9:00 AM – 11:00 AM ET
Indicators of Effectiveness After 6 Years of Follow-up in a Fracture Liaison Service Antonio Naranjo, PhD – Hospital Universitario de Gran Canaria Dr Negrin
9:00 AM – 11:00 AM ET
Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes Donna M. Jose, MD – Loma Linda University Medical Center
9:00 AM – 11:00 AM ET
Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases Giovanni Adami, MD – University of Verona, Italy
9:00 AM – 11:00 AM ET
Association of Low Bone Density with Need for Early Revision After Elective Joint Replacement for Osteoarthritis in Postmenopausal Women Rashmi Dhital, MD – Reading Hospital
9:00 AM – 11:00 AM ET
Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry Nitasha Khullar, MD – University of Alabama Birmingham
9:00 AM – 11:00 AM ET
Aromatase Inhibitor-Associated Bone Loss: Screening and Prevention Matthew J. White, DO – Dartmouth Hitchcock Medical Center
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic Catherine M. Teskin, DO – Christiana Care/Sidney Kimmel Medical College at Thomas Jefferson Univ.
9:00 AM – 11:00 AM ET
Immunophenotyping of Peripheral Blood Highlights an Association of Dysregulated Lymphocytes with Patients with Glucocorticoid-induced Osteonecrosis KAICHI KANEKO, MD, PhD – Hospital for Special Surgery
9:00 AM – 11:00 AM ET
Biochemical Algorithm to Identify Individuals with ALPL Variants Between Subjects with Persistent Hypophosphatasaemia Carolina Tornero-Marin, RhMSUS – La Paz Hospital
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density Edgar Wiebe – Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology
9:00 AM – 11:00 AM ET
The Prevalence of Osteoporosis in Individuals with Osteoarthritis: A Systematic Review Timothy Varghese, BSc – Schulich School of Medicine & Dentistry
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment Edgar Wiebe – Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology
